Form 4: ADC Therapeutics Director Receives RSU Grant

ADC Therapeutics SA reports a Form 4 filing detailing a director's receipt of restricted stock units and subsequent tax withholding.

Summary

• Viviane Monges, a Director at ADC Therapeutics SA, received an annual grant of 45,000 restricted stock units (RSUs) on June 1, 2026.
• These RSUs are part of the Issuer's 2019 Equity Incentive Plan and are intended as compensation for her services as a Director.
• The RSUs vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, contingent on continued service.
• On June 3, 2026, 2,596 common shares were withheld by the Issuer to cover tax obligations related to the vesting of prior restricted share units.
• Following these transactions, Monges beneficially owns 186,447 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine compensation and tax-related share withholding for a director, rather than significant new strategic or financial developments.

Positives

• Director Viviane Monges received a significant grant of 45,000 RSUs, indicating continued investment in key personnel.
• The RSUs are structured to vest over time, aligning the director's interests with long-term company performance.
• The company has a formal equity incentive plan in place to reward directors.

Negatives

• A portion of shares (2,596) were withheld for tax purposes, reducing the net shares received by the director.
• The filing does not provide details on the valuation of the RSU grant at the time of issuance.

Risks

• The vesting of RSUs is contingent upon the Reporting Person's continued service, implying a risk of forfeiture if service is terminated.
• The value of the RSUs is subject to the future performance and stock price of ADC Therapeutics SA.

Future Outlook

The restricted stock units granted to Viviane Monges are set to vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Shareholders, provided her service to the Issuer continues.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive and director compensation with shareholder value and long-term company growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns director incentives with long-term shareholder value creation. The tax withholding reduces the immediate number of shares held by the director.
• Employees: The filing pertains to director compensation and does not directly impact general employee compensation or benefits.
• Management: Viviane Monges, as a Director, is a key member of the leadership team whose compensation is being structured through equity awards.

Next Steps

• Vesting of the granted RSUs on the specified dates, subject to continued service.
• Potential future grants of equity compensation to directors and officers as part of the company's compensation strategy.

Key Dates

Keywords

Form 4, SEC Filing, ADC Therapeutics SA, ADCT, Viviane Monges, Director, Restricted Stock Units, RSU Grant, Equity Incentive Plan, Beneficial Ownership, Tax Withholding